Analysts have been eager to weigh in on the Healthcare sector with new ratings on McKesson (MCK – Research Report), Arcturus Therapeutics (ARCT – Research Report) and Neurocrine (NBIX – Research Report).
McKesson (MCK)
According to TipRanks.com, Grosslight is a 4-star analyst with an average return of
Currently, the analyst consensus on McKesson is a Strong Buy with an average price target of $542.50, a 6.4% upside from current levels. In a report issued on January 24, J.P. Morgan also maintained a Buy rating on the stock with a $564.00 price target.
See today’s best-performing stocks on TipRanks >>
Arcturus Therapeutics (ARCT)
The company’s shares closed last Wednesday at $37.30, close to its 52-week high of $38.27.
According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of
Arcturus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $74.80, implying a 98.3% upside from current levels. In a report issued on February 5, Wells Fargo also maintained a Buy rating on the stock with a $45.00 price target.
Neurocrine (NBIX)
The company’s shares closed last Wednesday at $136.29, close to its 52-week high of $143.35.
According to TipRanks.com, Hoang is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $142.50 average price target, implying a 5.6% upside from current levels. In a report issued on January 31, Mizuho Securities also maintained a Hold rating on the stock with a $116.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MCK:
